Search

Your search keyword '"Palmer, Daniel H"' showing total 473 results
Start Over Author "Palmer, Daniel H"
473 results on '"Palmer, Daniel H"'

5. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Author

Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, and Valle, Juan W

Published
2021
Full Text
View/download PDF

6. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

Author

Kudo, Masatoshi, Galle, Peter R., Brandi, Giovanni, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S., Llovet, Josep M., Assenat, Eric, Merle, Philippe, Chan, Stephen L., Palmer, Daniel H., Ikeda, Masafumi, Yamashita, Tatsuya, Vogel, Arndt, Huang, Yi-Hsiang, Abada, Paolo B., Yoshikawa, Reigetsu, Shinozaki, Kenta, Wang, Chunxiao, Widau, Ryan C., and Zhu, Andrew X.

Published
2021
Full Text
View/download PDF

9. The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial

Author

Loughney, Lisa, West, Malcolm A, Kemp, Graham J, Rossiter, Harry B, Burke, Shaunna M, Cox, Trevor, Barben, Christopher P, Mythen, Michael G, Calverley, Peter, Palmer, Daniel H, Grocott, Michael PW, and Jack, Sandy

Subjects
Biomedical and Clinical Sciences, Health Sciences, Clinical Sciences, Sports Science and Exercise, Cardiovascular, Cancer, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, 6.7 Physical, 6.4 Surgery, Evaluation of treatments and therapeutic interventions, Chemoradiotherapy, Clinical Protocols, Data Interpretation, Statistical, Exercise Therapy, Humans, Outcome Assessment, Health Care, Physical Fitness, Quality of Life, Rectal Neoplasms, Neoadjuvant chemoradiotherapy, Exercise training, Physical activity, Surgery, Surgical outcome, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, General & Internal Medicine, Clinical sciences, Epidemiology, Health services and systems
Abstract

BackgroundThe standard treatment pathway for locally advanced rectal cancer is neoadjuvant chemoradiotherapy (CRT) followed by surgery. Neoadjuvant CRT has been shown to decrease physical fitness, and this decrease is associated with increased post-operative morbidity. Exercise training can stimulate skeletal muscle adaptations such as increased mitochondrial content and improved oxygen uptake capacity, both of which are contributors to physical fitness. The aims of the EMPOWER trial are to assess the effects of neoadjuvant CRT and an in-hospital exercise training programme on physical fitness, health-related quality of life (HRQoL), and physical activity levels, as well as post-operative morbidity and cancer staging.Methods/designThe EMPOWER Trial is a randomised controlled trial with a planned recruitment of 46 patients with locally advanced rectal cancer and who are undergoing neoadjuvant CRT and surgery. Following completion of the neoadjuvant CRT (week 0) prior to surgery, patients are randomised to an in-hospital exercise training programme (aerobic interval training for 6 to 9 weeks) or a usual care control group (usual care and no formal exercise training). The primary endpoint is oxygen uptake at lactate threshold ([Formula: see text] at [Formula: see text]) measured using cardiopulmonary exercise testing assessed over several time points throughout the study. Secondary endpoints include HRQoL, assessed using semi-structured interviews and questionnaires, and physical activity levels assessed using activity monitors. Exploratory endpoints include post-operative morbidity, assessed using the Post-Operative Morbidity Survey (POMS), and cancer staging, assessed by using magnetic resonance tumour regression grading.DiscussionThe EMPOWER trial is the first randomised controlled trial comparing an in-hospital exercise training group with a usual care control group in patients with locally advanced rectal cancer. This trial will allow us to determine whether exercise training following neoadjuvant CRT can improve physical fitness and activity levels, as well as other important clinical outcome measures such as HRQoL and post-operative morbidity. These results will aid the design of a large, multi-centre trial to determine whether an increase in physical fitness improves clinically relevant post-operative outcomes.Trial registrationClinicalTrials.gov NCT01914068 (received: 7 June 2013).SponsorUniversity Hospital Southampton NHS Foundation Trust.

Published
2016

12. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

Author

Primrose, JN, Fox, RP, Morement, H, Chan, O, Rees, C, Ma, YT, Hickish, T, Falk, S, Finch-Jones, M, Pope, I, Corrie, P, Crosby, T, Sothi, S, Sharkland, K, Adamson, D, Wall, L, Evans, J, Dent, J, Hombaiah, U, Iwuji, C, Anthoney, A, Bridgewater, J, Cunningham, D, Gillmore, R, Ross, P, Slater, S, Wasan, H, Waters, J, Valle, JW, Palmer, D, Malik, H, Neoptolemos, J, Faluyi, O, Sumpter, K, Dernedde, U, Maduhusudan, S, Cogill, G, Archer, C, Iveson, T, Wadsley, J, Darby, S, Peterson, M, Mukhtar, AA, Thorpe, JG, Bateman, A, Tsang, D, Cummins, S, Nolan, L, Beaumont, E, Prasad, R, Mirza, D, Stocken, D, Praseedom, R, Davidson, B, Raftery, J, Zhu, S, Garden, J, Stubbs, C, Coxon, F, Primrose, John N, Fox, Richard P, Palmer, Daniel H, Malik, Hassan Z, Prasad, Raj, Mirza, Darius, Anthony, Alan, Corrie, Pippa, Falk, Stephen, Finch-Jones, Meg, Wasan, Harpreet, Ross, Paul, Wall, Lucy, Wadsley, Jonathan, Evans, Jeff T R, Stocken, Deborah, Praseedom, Raaj, Ma, Yuk Ting, Davidson, Brian, Neoptolemos, John P, Iveson, Tim, Raftery, James, Zhu, Shihua, Cunningham, David, Garden, O James, Stubbs, Clive, Valle, Juan W, and Bridgewater, John

Published
2019
Full Text
View/download PDF

15. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma

Author

Mahajan, Ujjwal Mukund, Langhoff, Eno, Goni, Elisabetta, Costello, Eithne, Greenhalf, William, Halloran, Christopher, Ormanns, Steffen, Kruger, Stephan, Boeck, Stefan, Ribback, Silvia, Beyer, Georg, Dombroswki, Frank, Weiss, Frank-Ulrich, Neoptolemos, John P., Werner, Jens, D’Haese, Jan G., Bazhin, Alexandr, Peterhansl, Julian, Pichlmeier, Svenja, Büchler, Markus W., Kleeff, Jörg, Ganeh, Paula, Sendler, Matthias, Palmer, Daniel H., Kohlmann, Thomas, Rad, Roland, Regel, Ivonne, Lerch, Markus M., and Mayerle, Julia

Published
2018
Full Text
View/download PDF

17. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

Author

Meyer, Tim, Fox, Richard, Ma, Yuk Ting, Ross, Paul J, James, Martin W, Sturgess, Richard, Stubbs, Clive, Stocken, Deborah D, Wall, Lucy, Watkinson, Anthony, Hacking, Nigel, Evans, T R Jeffry, Collins, Peter, Hubner, Richard A, Cunningham, David, Primrose, John Neil, Johnson, Philip J, and Palmer, Daniel H

Published
2017
Full Text
View/download PDF

18. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial

Author

Middleton, Gary, Palmer, Daniel H, Greenhalf, William, Ghaneh, Paula, Jackson, Richard, Cox, Trevor, Evans, Anthony, Shaw, Victoria E, Wadsley, Jonathan, Valle, Juan W, Propper, David, Wasan, Harpreet, Falk, Stephen, Cunningham, David, Coxon, Fareeda, Ross, Paul, Madhusudan, Srinivasan, Wadd, Nick, Corrie, Pippa, Hickish, Tamas, Costello, Eithne, Campbell, Fiona, Rawcliffe, Charlotte, and Neoptolemos, John P

Published
2017
Full Text
View/download PDF

19. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Author

Neoptolemos, John P, Palmer, Daniel H, Ghaneh, Paula, Psarelli, Eftychia E, Valle, Juan W, Halloran, Christopher M, Faluyi, Olusola, O'Reilly, Derek A, Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R, Middleton, Gary William, Cummins, Sebastian, Ross, Paul J, Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ma, Yuk Ting, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Hackert, Thilo, Jackson, Richard, and Büchler, Markus W

Published
2017
Full Text
View/download PDF

22. Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

Author

Backen, Alison C., Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H, Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Pippa G., Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, McNamara, Mairéad G., Beare, Sandy, Bridgewater, John A., Dive, Caroline, and Valle, Juan W.

Published
2018
Full Text
View/download PDF

24. PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research

Author

Jones, Robert P, primary, Mielgo, Ainhoa, additional, Schmid, Michael, additional, Bury, Danielle, additional, Andrews, Timothy, additional, Burdak-Rothkamm, Susanne, additional, Shackcloth, Michael, additional, J. S. Cross, Timothy, additional, Fenwick, Stephen, additional, Malik, Hassan Z, additional, Diaz-Nieto, Rafa, additional, Ottensmeier, Christian, additional, Palmer, Daniel H, additional, and Vimalachandran, Dale, additional

Published
2023
Full Text
View/download PDF

25. Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Author

Kim, Richard D., primary, Sarker, Debashis, primary, Meyer, Tim, primary, Yau, Thomas, primary, Macarulla, Teresa, primary, Park, Joong-Won, primary, Choo, Su Pin, primary, Hollebecque, Antoine, primary, Sung, Max W., primary, Lim, Ho-Yeong, primary, Mazzaferro, Vincenzo, primary, Trojan, Joerg, primary, Zhu, Andrew X., primary, Yoon, Jung-Hwan, primary, Sharma, Sunil, primary, Lin, Zhong-Zhe, primary, Chan, Stephen L., primary, Faivre, Sandrine, primary, Feun, Lynn G., primary, Yen, Chia-Jui, primary, Dufour, Jean-Francois, primary, Palmer, Daniel H., primary, Llovet, Josep M., primary, Manoogian, Melissa, primary, Tugnait, Meera, primary, Stransky, Nicolas, primary, Hagel, Margit, primary, Kohl, Nancy E., primary, Lengauer, Christoph, primary, Sherwin, Cori Ann, primary, Schmidt-Kittler, Oleg, primary, Hoeflich, Klaus P., primary, Shi, Hongliang, primary, Wolf, Beni B., primary, and Kang, Yoon-Koo, primary

Published
2023
Full Text
View/download PDF

26. Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Author

Kim, Richard D., primary, Sarker, Debashis, primary, Meyer, Tim, primary, Yau, Thomas, primary, Macarulla, Teresa, primary, Park, Joong-Won, primary, Choo, Su Pin, primary, Hollebecque, Antoine, primary, Sung, Max W., primary, Lim, Ho-Yeong, primary, Mazzaferro, Vincenzo, primary, Trojan, Joerg, primary, Zhu, Andrew X., primary, Yoon, Jung-Hwan, primary, Sharma, Sunil, primary, Lin, Zhong-Zhe, primary, Chan, Stephen L., primary, Faivre, Sandrine, primary, Feun, Lynn G., primary, Yen, Chia-Jui, primary, Dufour, Jean-Francois, primary, Palmer, Daniel H., primary, Llovet, Josep M., primary, Manoogian, Melissa, primary, Tugnait, Meera, primary, Stransky, Nicolas, primary, Hagel, Margit, primary, Kohl, Nancy E., primary, Lengauer, Christoph, primary, Sherwin, Cori Ann, primary, Schmidt-Kittler, Oleg, primary, Hoeflich, Klaus P., primary, Shi, Hongliang, primary, Wolf, Beni B., primary, and Kang, Yoon-Koo, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Legends from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Sarker, Debashis, primary, Plummer, Ruth, primary, Meyer, Tim, primary, Sodergren, Mikael H., primary, Basu, Bristi, primary, Chee, Cheng Ean, primary, Huang, Kai-Wen, primary, Palmer, Daniel H., primary, Ma, Yuk Ting, primary, Evans, T.R. Jeff, primary, Spalding, Duncan R.C., primary, Pai, Madhava, primary, Sharma, Rohini, primary, Pinato, David J., primary, Spicer, James, primary, Hunter, Sarah, primary, Kwatra, Vineet, primary, Nicholls, Joanna P., primary, Collin, David, primary, Nutbrown, Robert, primary, Glenny, Helen, primary, Fairbairn, Sonia, primary, Reebye, Vikash, primary, Voutila, Jon, primary, Dorman, Stephanie, primary, Andrikakou, Pinelopi, primary, Lloyd, Peter, primary, Felstead, Steve, primary, Vasara, Jenni, primary, Habib, Robert, primary, Wood, Chris, primary, Saetrom, Pal, primary, Huber, Hans E., primary, Blakey, David C., primary, Rossi, John J., primary, and Habib, Nagy, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 4 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Sarker, Debashis, primary, Plummer, Ruth, primary, Meyer, Tim, primary, Sodergren, Mikael H., primary, Basu, Bristi, primary, Chee, Cheng Ean, primary, Huang, Kai-Wen, primary, Palmer, Daniel H., primary, Ma, Yuk Ting, primary, Evans, T.R. Jeff, primary, Spalding, Duncan R.C., primary, Pai, Madhava, primary, Sharma, Rohini, primary, Pinato, David J., primary, Spicer, James, primary, Hunter, Sarah, primary, Kwatra, Vineet, primary, Nicholls, Joanna P., primary, Collin, David, primary, Nutbrown, Robert, primary, Glenny, Helen, primary, Fairbairn, Sonia, primary, Reebye, Vikash, primary, Voutila, Jon, primary, Dorman, Stephanie, primary, Andrikakou, Pinelopi, primary, Lloyd, Peter, primary, Felstead, Steve, primary, Vasara, Jenni, primary, Habib, Robert, primary, Wood, Chris, primary, Saetrom, Pal, primary, Huber, Hans E., primary, Blakey, David C., primary, Rossi, John J., primary, and Habib, Nagy, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Author

Verset, Gontran, primary, Borbath, Ivan, primary, Karwal, Mark, primary, Verslype, Chris, primary, Van Vlierberghe, Hans, primary, Kardosh, Adel, primary, Zagonel, Vittorina, primary, Stal, Per, primary, Sarker, Debashis, primary, Palmer, Daniel H., primary, Vogel, Arndt, primary, Edeline, Julien, primary, Cattan, Stephane, primary, Kudo, Masatoshi, primary, Cheng, Ann-Lii, primary, Ogasawara, Sadahisa, primary, Daniele, Bruno, primary, Chan, Stephen L., primary, Knox, Jennifer J., primary, Qin, Shukui, primary, Siegel, Abby B., primary, Chisamore, Michael, primary, Hatogai, Ken, primary, Wang, Anran, primary, Finn, Richard S., primary, and Zhu, Andrew X., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 3 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Sarker, Debashis, primary, Plummer, Ruth, primary, Meyer, Tim, primary, Sodergren, Mikael H., primary, Basu, Bristi, primary, Chee, Cheng Ean, primary, Huang, Kai-Wen, primary, Palmer, Daniel H., primary, Ma, Yuk Ting, primary, Evans, T.R. Jeff, primary, Spalding, Duncan R.C., primary, Pai, Madhava, primary, Sharma, Rohini, primary, Pinato, David J., primary, Spicer, James, primary, Hunter, Sarah, primary, Kwatra, Vineet, primary, Nicholls, Joanna P., primary, Collin, David, primary, Nutbrown, Robert, primary, Glenny, Helen, primary, Fairbairn, Sonia, primary, Reebye, Vikash, primary, Voutila, Jon, primary, Dorman, Stephanie, primary, Andrikakou, Pinelopi, primary, Lloyd, Peter, primary, Felstead, Steve, primary, Vasara, Jenni, primary, Habib, Robert, primary, Wood, Chris, primary, Saetrom, Pal, primary, Huber, Hans E., primary, Blakey, David C., primary, Rossi, John J., primary, and Habib, Nagy, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Author

Verset, Gontran, primary, Borbath, Ivan, primary, Karwal, Mark, primary, Verslype, Chris, primary, Van Vlierberghe, Hans, primary, Kardosh, Adel, primary, Zagonel, Vittorina, primary, Stal, Per, primary, Sarker, Debashis, primary, Palmer, Daniel H., primary, Vogel, Arndt, primary, Edeline, Julien, primary, Cattan, Stephane, primary, Kudo, Masatoshi, primary, Cheng, Ann-Lii, primary, Ogasawara, Sadahisa, primary, Daniele, Bruno, primary, Chan, Stephen L., primary, Knox, Jennifer J., primary, Qin, Shukui, primary, Siegel, Abby B., primary, Chisamore, Michael, primary, Hatogai, Ken, primary, Wang, Anran, primary, Finn, Richard S., primary, and Zhu, Andrew X., primary

Published
2023
Full Text
View/download PDF

34. Data from Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer

Author

Quaranta, Valeria, primary, Rainer, Carolyn, primary, Nielsen, Sebastian R., primary, Raymant, Meirion L., primary, Ahmed, Muhammad S., primary, Engle, Dannielle D., primary, Taylor, Arthur, primary, Murray, Trish, primary, Campbell, Fiona, primary, Palmer, Daniel H., primary, Tuveson, David A., primary, Mielgo, Ainhoa, primary, and Schmid, Michael C., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Author

Verset, Gontran, primary, Borbath, Ivan, primary, Karwal, Mark, primary, Verslype, Chris, primary, Van Vlierberghe, Hans, primary, Kardosh, Adel, primary, Zagonel, Vittorina, primary, Stal, Per, primary, Sarker, Debashis, primary, Palmer, Daniel H., primary, Vogel, Arndt, primary, Edeline, Julien, primary, Cattan, Stephane, primary, Kudo, Masatoshi, primary, Cheng, Ann-Lii, primary, Ogasawara, Sadahisa, primary, Daniele, Bruno, primary, Chan, Stephen L., primary, Knox, Jennifer J., primary, Qin, Shukui, primary, Siegel, Abby B., primary, Chisamore, Michael, primary, Hatogai, Ken, primary, Wang, Anran, primary, Finn, Richard S., primary, and Zhu, Andrew X., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 5 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Sarker, Debashis, primary, Plummer, Ruth, primary, Meyer, Tim, primary, Sodergren, Mikael H., primary, Basu, Bristi, primary, Chee, Cheng Ean, primary, Huang, Kai-Wen, primary, Palmer, Daniel H., primary, Ma, Yuk Ting, primary, Evans, T.R. Jeff, primary, Spalding, Duncan R.C., primary, Pai, Madhava, primary, Sharma, Rohini, primary, Pinato, David J., primary, Spicer, James, primary, Hunter, Sarah, primary, Kwatra, Vineet, primary, Nicholls, Joanna P., primary, Collin, David, primary, Nutbrown, Robert, primary, Glenny, Helen, primary, Fairbairn, Sonia, primary, Reebye, Vikash, primary, Voutila, Jon, primary, Dorman, Stephanie, primary, Andrikakou, Pinelopi, primary, Lloyd, Peter, primary, Felstead, Steve, primary, Vasara, Jenni, primary, Habib, Robert, primary, Wood, Chris, primary, Saetrom, Pal, primary, Huber, Hans E., primary, Blakey, David C., primary, Rossi, John J., primary, and Habib, Nagy, primary

Published
2023
Full Text
View/download PDF

37. Appendix A from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Sarker, Debashis, primary, Plummer, Ruth, primary, Meyer, Tim, primary, Sodergren, Mikael H., primary, Basu, Bristi, primary, Chee, Cheng Ean, primary, Huang, Kai-Wen, primary, Palmer, Daniel H., primary, Ma, Yuk Ting, primary, Evans, T.R. Jeff, primary, Spalding, Duncan R.C., primary, Pai, Madhava, primary, Sharma, Rohini, primary, Pinato, David J., primary, Spicer, James, primary, Hunter, Sarah, primary, Kwatra, Vineet, primary, Nicholls, Joanna P., primary, Collin, David, primary, Nutbrown, Robert, primary, Glenny, Helen, primary, Fairbairn, Sonia, primary, Reebye, Vikash, primary, Voutila, Jon, primary, Dorman, Stephanie, primary, Andrikakou, Pinelopi, primary, Lloyd, Peter, primary, Felstead, Steve, primary, Vasara, Jenni, primary, Habib, Robert, primary, Wood, Chris, primary, Saetrom, Pal, primary, Huber, Hans E., primary, Blakey, David C., primary, Rossi, John J., primary, and Habib, Nagy, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Sarker, Debashis, primary, Plummer, Ruth, primary, Meyer, Tim, primary, Sodergren, Mikael H., primary, Basu, Bristi, primary, Chee, Cheng Ean, primary, Huang, Kai-Wen, primary, Palmer, Daniel H., primary, Ma, Yuk Ting, primary, Evans, T.R. Jeff, primary, Spalding, Duncan R.C., primary, Pai, Madhava, primary, Sharma, Rohini, primary, Pinato, David J., primary, Spicer, James, primary, Hunter, Sarah, primary, Kwatra, Vineet, primary, Nicholls, Joanna P., primary, Collin, David, primary, Nutbrown, Robert, primary, Glenny, Helen, primary, Fairbairn, Sonia, primary, Reebye, Vikash, primary, Voutila, Jon, primary, Dorman, Stephanie, primary, Andrikakou, Pinelopi, primary, Lloyd, Peter, primary, Felstead, Steve, primary, Vasara, Jenni, primary, Habib, Robert, primary, Wood, Chris, primary, Saetrom, Pal, primary, Huber, Hans E., primary, Blakey, David C., primary, Rossi, John J., primary, and Habib, Nagy, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Tables from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Sarker, Debashis, primary, Plummer, Ruth, primary, Meyer, Tim, primary, Sodergren, Mikael H., primary, Basu, Bristi, primary, Chee, Cheng Ean, primary, Huang, Kai-Wen, primary, Palmer, Daniel H., primary, Ma, Yuk Ting, primary, Evans, T.R. Jeff, primary, Spalding, Duncan R.C., primary, Pai, Madhava, primary, Sharma, Rohini, primary, Pinato, David J., primary, Spicer, James, primary, Hunter, Sarah, primary, Kwatra, Vineet, primary, Nicholls, Joanna P., primary, Collin, David, primary, Nutbrown, Robert, primary, Glenny, Helen, primary, Fairbairn, Sonia, primary, Reebye, Vikash, primary, Voutila, Jon, primary, Dorman, Stephanie, primary, Andrikakou, Pinelopi, primary, Lloyd, Peter, primary, Felstead, Steve, primary, Vasara, Jenni, primary, Habib, Robert, primary, Wood, Chris, primary, Saetrom, Pal, primary, Huber, Hans E., primary, Blakey, David C., primary, Rossi, John J., primary, and Habib, Nagy, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 2 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Sarker, Debashis, primary, Plummer, Ruth, primary, Meyer, Tim, primary, Sodergren, Mikael H., primary, Basu, Bristi, primary, Chee, Cheng Ean, primary, Huang, Kai-Wen, primary, Palmer, Daniel H., primary, Ma, Yuk Ting, primary, Evans, T.R. Jeff, primary, Spalding, Duncan R.C., primary, Pai, Madhava, primary, Sharma, Rohini, primary, Pinato, David J., primary, Spicer, James, primary, Hunter, Sarah, primary, Kwatra, Vineet, primary, Nicholls, Joanna P., primary, Collin, David, primary, Nutbrown, Robert, primary, Glenny, Helen, primary, Fairbairn, Sonia, primary, Reebye, Vikash, primary, Voutila, Jon, primary, Dorman, Stephanie, primary, Andrikakou, Pinelopi, primary, Lloyd, Peter, primary, Felstead, Steve, primary, Vasara, Jenni, primary, Habib, Robert, primary, Wood, Chris, primary, Saetrom, Pal, primary, Huber, Hans E., primary, Blakey, David C., primary, Rossi, John J., primary, and Habib, Nagy, primary

Published
2023
Full Text
View/download PDF

41. Data Supplement from Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer

Author

Quaranta, Valeria, primary, Rainer, Carolyn, primary, Nielsen, Sebastian R., primary, Raymant, Meirion L., primary, Ahmed, Muhammad S., primary, Engle, Dannielle D., primary, Taylor, Arthur, primary, Murray, Trish, primary, Campbell, Fiona, primary, Palmer, Daniel H., primary, Tuveson, David A., primary, Mielgo, Ainhoa, primary, and Schmid, Michael C., primary

Published
2023
Full Text
View/download PDF

42. The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer

Author

Ahmed, Ahmed A., primary, Greenhalf, William, additional, Palmer, Daniel H., additional, Williams, Nicole, additional, Worthington, Jenny, additional, Arshad, Tariq, additional, Haider, Shozeb, additional, Alexandrou, Effrosyni, additional, Guneri, Dilek, additional, Waller, Zoe A. E., additional, and Neidle, Stephen, additional

Published
2023
Full Text
View/download PDF

43. A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Author

Evans, T.R. Jeffry, primary, Basu, Bristi, additional, Hubner, Richard, additional, Ma, Yuk Ting, additional, Meyer, Tim, additional, Palmer, Daniel H., additional, Pinato, David J. James, additional, Plummer, Elizabeth Ruth, additional, Ross, Paul J., additional, Samson, Adel, additional, Sarker, Debashis, additional, Kendall, Timothy, additional, Bellamy, Christopher, additional, Reeves, Helen L, additional, Thomson, Fiona, additional, Lawless, Claire A, additional, Stobo, Jamie, additional, Sansom, Owen J, additional, Mann, Derek A., additional, and Bird, Thomas G, additional

Published
2023
Full Text
View/download PDF

45. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

Author

Valle, Juan W, Wasan, Harpreet, Lopes, Andre, Backen, Alison C, Palmer, Daniel H, Morris, Karen, Duggan, Marian, Cunningham, David, Anthoney, D Alan, Corrie, Pippa, Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J, Waters, Justin S, Steward, Will P, Rees, Charlotte, Beare, Sandy, Dive, Caroline, and Bridgewater, John A

Published
2015
Full Text
View/download PDF

47. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma

Author

de Andrés, Mónica P, primary, Jackson, Richard J, additional, Felipe, Irene, additional, Zagorac, Sladjana, additional, Pilarsky, Christian, additional, Schlitter, Anna Melissa, additional, Martinez de Villareal, Jaime, additional, Jang, Gun Ho, additional, Costello, Eithne, additional, Gallinger, Steve, additional, Ghaneh, Paula, additional, Greenhalf, William, additional, Knösel, Thomas, additional, Palmer, Daniel H, additional, Ruemmele, Petra, additional, Weichert, Wilko, additional, Buechler, Markus, additional, Hackert, Thilo, additional, Neoptolemos, John P, additional, Notta, Faiyaz, additional, Malats, Núria, additional, Martinelli, Paola, additional, and Real, Francisco X, additional

Published
2022
Full Text
View/download PDF

49. A randomised phase II clinical trial of low-dose cyclophosphamide and transarterial chemoembolization (TACE) with or without vaccination with dendritic cells (DC) pulsed with HepG2 lysate ex vivo in patients with hepatocellular carcinoma (HCC): The ImmunoTACE trial.

Author

Ma, Yuk Ting, primary, Kirkham, Amanda, additional, Curbishley, Stuart, additional, Rowe, Anna, additional, Blahova, Miroslava, additional, Mehrzad, Homoyon, additional, Karkhanis, Salil, additional, Punia, Pankaj, additional, James, Martin, additional, Rao, Ankit Rohit, additional, Stern, Nick, additional, Palmer, Daniel H., additional, Hull, Diana, additional, Lowe, Faye, additional, Douglas-Pugh, Jessica, additional, Bathurst, Camilla, additional, Wilkhu, Manpreet, additional, Yap, Christina, additional, and Adams, David H, additional

Published
2022
Full Text
View/download PDF

50. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.

Author

Borbath, Ivan, primary, Van Laethem, Jean-Luc, additional, Karwal, Mark, additional, Verslype, Chris, additional, Van Vlierberghe, Hans, additional, Kardosh, Adel, additional, Bergamo, Francesca, additional, Stål, Per, additional, Sarker, Debashis, additional, Palmer, Daniel H., additional, Edeline, Julien, additional, Cattan, Stéphane, additional, Kudo, Masatoshi, additional, Cheng, Ann-Lii, additional, Ogasawara, Sadahisa, additional, Siegel, Abby B., additional, Hatogai, Ken, additional, Wang, Anran, additional, and Vogel, Arndt, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results